Objective - To assess the impact of achieving Lupus Low Disease Activity State ≥50% of the time (LLDAS‐50) on damage accrual and mortality in an inception cohort of patients with systemic lupus erythematosus (SLE). Methods - We used data from the Tromsø Lupus Cohort, a longitudinal population‐based study of all patients with SLE in the 2 northernmost counties in Norway. LLDAS was defined as 1) a Systemic Lupus Erythematosus Disease Activity Index 2000 score of ≤4, with no activity in major organ systems, 2) no new features of lupus disease activity, 3) current therapy with prednisolone (or equivalent) dosage of ≤7.5 mg daily, and 4) well‐tolerated standard maintenance dosages of immunosuppressive drugs. Results - A total of 69 patients...
Abstract Background The aim was to assess the attainability and outcome of the lupus low disease act...
OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for ...
Background: The aim was to assess the attainability and outcome of the lupus low disease activity st...
OBJECTIVE: To evaluate the prevalence, duration and effect on damage accrual of the 'Lupus Low Dise...
Objective To determine if achieving lupus low disease activity state (LLDAS) or remission prevents d...
OBJECTIVE: To determine the independent impact of different definitions of remission and low disease...
Objective: To determine the independent impact of different definitions of remission and low disease...
Objectives: To compare the effect of achievement and maintenance of lupus low disease activity state...
Objective: To determine the independent impact of different definitions of remission and low disease...
Background: Systemic lupus erythematosus (SLE) is a chronic heterogeneous disease with considerable ...
Objective: To determine the independent impact of different definitions of remission and low disease...
Objectives: To compare the effect of achievement and maintenance of lupus low disease activity state...
BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic heterogeneous disease with considerable ...
The principle of “Treating-to-target” has been widely applied to the management of rheumatic disease...
Plenary Session 5: Outcome measures and treatment targets in SLEBackground and aims While a 'Treat-t...
Abstract Background The aim was to assess the attainability and outcome of the lupus low disease act...
OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for ...
Background: The aim was to assess the attainability and outcome of the lupus low disease activity st...
OBJECTIVE: To evaluate the prevalence, duration and effect on damage accrual of the 'Lupus Low Dise...
Objective To determine if achieving lupus low disease activity state (LLDAS) or remission prevents d...
OBJECTIVE: To determine the independent impact of different definitions of remission and low disease...
Objective: To determine the independent impact of different definitions of remission and low disease...
Objectives: To compare the effect of achievement and maintenance of lupus low disease activity state...
Objective: To determine the independent impact of different definitions of remission and low disease...
Background: Systemic lupus erythematosus (SLE) is a chronic heterogeneous disease with considerable ...
Objective: To determine the independent impact of different definitions of remission and low disease...
Objectives: To compare the effect of achievement and maintenance of lupus low disease activity state...
BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic heterogeneous disease with considerable ...
The principle of “Treating-to-target” has been widely applied to the management of rheumatic disease...
Plenary Session 5: Outcome measures and treatment targets in SLEBackground and aims While a 'Treat-t...
Abstract Background The aim was to assess the attainability and outcome of the lupus low disease act...
OBJECTIVE: Treat-to-target end points for systemic lupus erythematosus (SLE) have been assessed for ...
Background: The aim was to assess the attainability and outcome of the lupus low disease activity st...